| Ocular Hypertension
Combigan vs Vyzulta
Side-by-side clinical, coverage, and cost comparison for ocular hypertension.Deep comparison between: Combigan vs Vyzulta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyzulta has a higher rate of injection site reactions vs Combigan based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyzulta but not Combigan, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Combigan
Vyzulta
At A Glance
Topical (ophthalmic)
Twice daily
Alpha-2 agonist / beta-blocker
Topical ophthalmic
Once daily
Prostaglandin analog
Indications
- Glaucoma
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Ocular Hypertension One drop in the affected eye(s) twice daily approximately 12 hours apart; if using multiple topical ophthalmic products, instill at least 5 minutes apart.
Glaucoma, Open-Angle, Ocular Hypertension One drop in the conjunctival sac of the affected eye(s) once daily in the evening; do not administer more than once daily.
Contraindications
- Bronchial asthma, history of bronchial asthma, or severe chronic obstructive pulmonary disease
- Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock
- Neonates and infants (pediatric patients younger than 2 years old)
- Hypersensitivity to any component of this product
—
Adverse Reactions
Most common (5%-15%) allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, stinging
Serious hypersensitivity reactions, severe respiratory or cardiac reactions, cardiac failure, potentiation of vascular insufficiency, increased reactivity to allergens, potentiation of muscle weakness, masking of hypoglycemia, masking of thyrotoxicosis, ocular hypersensitivity
Postmarketing bradycardia, eyelid erythema, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions, syncope, tachycardia
Most common (>=2%) conjunctival hyperemia, eye irritation, eye pain, instillation site pain
Pharmacology
COMBIGAN combines brimonidine tartrate, a relatively selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow, with timolol maleate, a non-selective beta-1 and beta-2 adrenergic receptor inhibitor, to lower elevated intraocular pressure.
Latanoprostene bunod is a prostaglandin analog and nitric oxide-donating agent that lowers intraocular pressure by increasing aqueous humor outflow through both the trabecular meshwork and uveoscleral routes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Combigan
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Vyzulta
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Combigan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Vyzulta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Combigan
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Vyzulta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Combigan.
No savings programs available for Vyzulta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CombiganView full Combigan profile
VyzultaView full Vyzulta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.